DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, this will not stop me, Only God and death can..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai), INDIA, worlddrugtracker, 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.8 Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution
n, सुकून उतना ही देना प्रभू, जितने से जिंदगी चल जाये।औकात बस इतनी देना,कि औरों का भला हो जाये।...........P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.
Showing posts with label GDC-0919; NLG-919; RG-6078. Show all posts
Showing posts with label GDC-0919; NLG-919; RG-6078. Show all posts

Tuesday 5 April 2016

GDC-0919; NLG-919; RG-6078



img
MF C18H22N2O
MW: 282.17321
GDC-0919; NLG-919; RG-6078, GDC0919; GDC-0919; GDC 0919; NLG919; NLG 919; NLG-919; RG6078; RG-6078; RG 6078.
 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol
CAS No.1402836-58-1
GDC-0919, also known as NLG919 and RG6078, is an orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, NLG919 targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the essential amino acid tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, this agent increases tryptophan levels, restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells

  • Originator Lankenau Institute for Medical Research
  • Developer Genentech; NewLink Genetics Corporation
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Immunomodulators; Indoleamine-pyrrole 2,3-dioxygenase inhibitors
Phase I Solid tumours
Patent ID Date Patent Title
US2015210769 2015-07-30 ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
US2014066625 2014-03-06 Fused Imidazole Derivatives Useful as IDO Inhibitors
  • 27 Sep 2015 Pharmacokinetics results from a phase-I clinical trial in Solid tumours presented at the European Cancer Congress 2015 (ECC-2015)
  • 27 Sep 2015 Positive efficacy and safety results from a phase-I clinical trial in Solid tumours presented at the European Cancer Congress 2015 (ECC-2015)
  • 31 Jul 2015 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT02471846)
PATENT
http://www.google.com/patents/WO2012142237A1?cl=en
str1
PATENT
US-20160002249-A1 / 2016-01-07

Fused Imidazole Derivatives Useful as IDO Inhibitors

1304Image loading...1-cyclohexyl-2-(5H-imidazo[5,1- a]isoindol-5-yl)ethanol79 1H NMR (a mixture of diastereomers) 1.10-1.37 (m, 6H), 1.66-1.80 (m, 5H), 2.05 (m, 2H), 2.15 (m, 1H), 3.72 (m, 1H), 5.36 and 5.46 (two m, 1H), 7.16 (s, 1H), 7.25 (m, 1H), 7.34 (m, 1H), 7.43 (d, 1H, J = 7.6 Hz), 7.54 (d, 1H, J = 7.6 Hz), 7.80 (s, 1H)
WO2011056652A1 * Oct 27, 2010 May 12, 2011 Newlink Genetics Imidazole derivatives as ido inhibitors
WO2012142237A1 * Apr 12, 2012 Oct 18, 2012 Newlink Geneticks Corporation Fused imidazole derivatives useful as ido inhibitors
WO2014159248A1 Mar 10, 2014 Oct 2, 2014 Newlink Genetics Corporation Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
US8722720 Oct 27, 2010 May 13, 2014 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
US9260434 Oct 14, 2013 Feb 16, 2016 Newlink Genetics Corporation Fused imidazole derivatives useful as IDO inhibitors
US20140066625 * Oct 14, 2013 Mar 6, 2014 Newlink Genetics Corporation Fused Imidazole Derivatives Useful as IDO Inhibitors
US20160002249 * Jul 8, 2015 Jan 7, 2016 Newlink Genetics Corporation Fused Imidazole Derivatives Useful as IDO Inhibitors
REFERENCES
Nature Reviews Drug Discovery14,373(2015)doi:10.1038/nrd4658
http://www.ncbi.nlm.nih.gov/pubmed/21517759
http://www.roche.com/irp150128-annex.pdf
/////CRD1152, CRD 1152, CRD-1152, Curadev,  Research Collaboration, Licensing Agreement, Develop,  Cancer Immunotherapeutic, IDO1 and TDO inhibitors
img
OC(C1CCCCC1)CC(C2=C3C=CC=C2)N4C3=CN=C4